What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 Trials
نویسندگان
چکیده
منابع مشابه
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
Initial human immunodeficiency virus (HIV) vaccines are unlikely to prevent acquisition of HIV in all recipients. Moreover, several HIV vaccines are under evaluation that are designed to reduce viremia after acquisition of infection. Such vaccines could provide important benefits to delay HIV progression and to reduce transmission. The decision to license a vaccine on the basis of observed effe...
متن کاملHuman immunodeficiency virus vaccine trials.
More than 2 million AIDS-related deaths occurred globally in 2008, and more than 33 million people are living with HIV/AIDS. Despite promising advances in prevention, an estimated 2.7 million new HIV infections occurred in that year, so that for every two patients placed on combination antiretroviral treatment, five people became infected. The pandemic poses a formidable challenge to the develo...
متن کاملSurrogate end points for clinical trials of kidney disease progression.
C hronic kidney disease (CKD) worsens over time by transitions through a sequence of stages, regardless of the specific cause of kidney damage or rate of progression (Figure 1). Recent guidelines and public health campaigns have focused on early detection and treatment of CKD on the basis of the rationale that treatments that are initiated early in the disease course will have a greater effect ...
متن کاملSurrogate end points in clinical trials: are we being misled?
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or other major symptomatic event), often require many participants to be followed for a long time.There has recently been great interest in using surrogate end points, such as tumor shrinkage or changes in cholesterol leve...
متن کاملAre surrogate end points in drug-eluting stent trials reliable?
5-lipoxygenase gene disruption reduces amyloidpathology in a mouse model of Alzheimer’s disease. FASEB J 2008;22:1169 –78. 6. Manev R, Imbesi M, Uz T, Dzitoyeva S, Dimitrijevic N, Manev H. Effects of 5-lipoxygenase inhibitors MK-886 and caffeic acid in a model of forced swimming in wild-type and 5-lipoxygenase– deficient mice. Program 711.4/BB17. 2007 Neuroscience Meeting Planner. San Diego, CA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Infectious Diseases
سال: 2003
ISSN: 0022-1899,1537-6613
DOI: 10.1086/376449